Clinical Trial Update: Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ziv-Aflibercept for pancreatic neuroendocrine tumors; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Endocrine Neoplasia Type
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Ziv-aflibercept (ziv-aflibercept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-23